VivaGel BV granted QIDP and Fast Track designation by US FDA
Filed with ASX · · 3 pages · English
Starpharma Holdings Limited on 6ix
Earlier from Starpharma
- Starpharma receives $3.5M R&D tax incentive refund
- Starpharma signs license for VivaGel Condom in Iran
- Additional Priostar Glyphosate Patent Allowed in US
- Enrolment complete for Phase 3 VivaGel BV-R program
- VivaGel condom receives regulatory approval in Canada
Later from Starpharma
- Shareholder Update January 2017
- VivaGel BV phase 3 trials for prevention of BV completed
- Ansell launches VivaGel condom in Canada
- AstraZeneca DEP candidate advance triggers milestone to SPL
- DEP irinotecan outperforms irinotecan in cancer models
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma